Table 3.
Clinical studies targeting NOS/NO in ED
| Therapy | Drug dose | Patients | Sexual function | References |
|---|---|---|---|---|
| L-arginine supplementation | L-arginine 3 × 500 mg·day−1 | 32 patients with mixed-type impotence | No difference | Klotz et al., 1999 |
| L-arginine (5 g·day−1) | 50 organic ED patients. A double-blind, randomized, placebo-controlled study. | Significant improvement | Chen et al., 1999 | |
| BH4 supplementation | Single oral doses of BH4 200 mg or 500 mg | 18 moderate ED patients in a randomized, placebo-controlled, double-blind crossover study. | Increase duration of penile rigidity. | Sommer et al., 2006 |
| Combined therapies with L-arginine | L-arginine aspartate 8 g + adenosine monophosphate 200 mg | Mild-to-moderate ED whose erectile function domain score between 14 and 22 | Effective | Neuzillet et al., 2013 |
| L-arginine + L-carnitine + nicotinic acid + vardanafil | Insulin-dependent diabetic patients | Better than PDE-5 inhibitor alone | Gentile et al., 2009. | |
| L-arginine 6 g + yohimbine 6 g during 2 weeks or L-arginine 6 g | 42 patients mild to moderate ED. Double-blind, placebo-controlled, three-way crossover, randomized clinical trial. | L-arginine do not improve alone but combined therapy improve erectile function | Lebret et al., 2002 | |
| L-arginine aspartate 1 g during 3 months + pycnogenol 3 × 40 mg during 2 months | 40 ED patients | Improve sexual function. | Stanislavov and Nikolova, 2003 |